研究者氏名	髙原健
	タカハラキヨシ
URL
所属	藤田医科大学
部署	医学部腎泌尿器外科
職名	准教授
学位	博士（医学）
J-Global ID	201701000378350191

研究キーワード

前立腺癌 ,腎癌 ,ロボット支援手術

研究分野

ライフサイエンス / 腫瘍診断、治療学 / 前立腺癌
ライフサイエンス / 泌尿器科学 /

経歴

12 >

2018年10月

現在

藤田医科大学医学部腎泌尿器外科准教授

2017年4月

2018年9月

藤田医科大学医学部腎泌尿器外科講師

2016年9月

2017年3月

大阪医科薬科大学医学部腎泌尿器外科

2015年10月

2016年8月

大阪医科薬科大学医学部腎泌尿器外科

2013年4月

2015年9月

大阪医科薬科大学医学部腎泌尿器外科助教

学歴

2009年4月

2013年3月

大阪医科薬科大学大学院医学研究科

1993年4月

1999年3月

大阪医科薬科大学医学部医学科

論文

<123 4 5 >

Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.

Takuhisa Nukaya Kiyoshi Takahara Atsuhiko Yoshizawa Masanobu Saruta Yusuke Yano Takaya Ohno Taizo Uchimoto Wataru Fukuokaya Takahiro Adachi Shogo Yamazaki Satoshi Tokushige Kazuki Nishimura Takuya Tsujino Keita Nakamori Shutaro Yamamoto Kosuke Iwatani Fumihiko Urabe Keiichiro Mori Takafumi Yanagisawa Shunsuke Tsuduki Yosuke Hirasawa Takeshi Hashimoto Kazumasa Komura Teruo Inamoto Jun Miki Takahiro Kimura Yoshio Ohno Haruhito Azuma Ryoichi Shiroki

Clinical genitourinary cancer 2023年10月

BACKGROUND: Immune checkpoint inhibitors can cause various immune-related adverse events (irAEs). This study aimed to evaluate the association between the incidence of irAEs and oncological outcomes of metastatic renal cell carcinoma (mRCC) treate...

Tertiary lymphoid structure and neutrophil–lymphocyte ratio coordinately predict outcome of pembrolizumab

Kazumasa Komura Satoshi Tokushige Mitsuaki Ishida Kensuke Hirosuna Shogo Yamazaki Kazuki Nishimura Masahiko Ajiro Takaya Ohno Keita Nakamori Shoko Kinoshita Takuya Tsujino Ryoichi Maenosono Yuki Yoshikawa Tomoaki Takai Takeshi Tsutsumi Kohei Taniguchi Tomohito Tanaka Kiyoshi Takahara Teruo Inamoto Yoshinobu Hirose Fumihito Ono Yuichi Shiraishi Akihide Yoshimi Haruhito Azuma

Cancer Science 2023年9月 [査読有り]

Abstract

Emerging evidence suggests that the presence of tertiary lymphoid structures (TLS) and neutrophil–lymphocyte ratio (NLR) in peripheral blood is associated with the treatment response to checkpoint inhibitors (CPIs), whereas there is limi...

Combination of deep learning and ensemble machine learning using intraoperative video images strongly predicts recovery of urinary continence after robot‐assisted radical prostatectomy

Wataru Nakamura Makoto Sumitomo Kenji Zennami Masashi Takenaka Manabu Ichino Kiyoshi Takahara Atsushi Teramoto Ryoichi Shiroki

Cancer Reports 2023年7月

Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence

Keita Nakane Hiromitsu Watanabe Taku Naiki Kiyoshi Takahara Takahiro Yasui Hideaki Miyake Ryoichi Shiroki Takuya Koie

Diagnostics 2023年5月

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.

Keita Nakamori Shogo Yamazaki Kazumasa Komura Wataru Fukuokaya Takahiro Adachi Yosuke Hirasawa Takeshi Hashimoto Atsuhiko Yoshizawa Takaya Ohno Yusuke Yano Kazuki Nishimura Satoshi Tokushige Taizo Uchimoto Shutaro Yamamoto Kosuke Iwatani Fumihiko Urabe Keiichiro Mori Takafumi Yanagisawa Shunsuke Tsuduki Kiyoshi Takahara Teruo Inamoto Jun Miki Takahiro Kimura Yoshio Ohno Ryoichi Shiroki Haruhito Azuma

Clinical and translational radiation oncology 39 100558-100558 2023年3月

BACKGROUND AND PURPOSE: Pembrolizumab has now become a standard of care in metastatic urothelial carcinoma (mUC), although the treatment effect of the drug substantially differs among individuals. Emerging evidence suggests that radiotherapy exert...